Intravesical epinephrine preserves uroplakin II expression in urinary bladder from cyclophosphamide-induced rat cystitis.
We investigated the attenuated effect of intravesical epinephrine (EPI) on uroplakin II (UPII) expression in cyclophosphamide (CYP)-induced rat cystitis. Sixty-eight Sprague-Dawley female rats were divided into one negative control group (GI) and five intraperitoneally CYP (150 mg CYP/kg)-injected groups (GII-VI) consisting of a positive control group (GII), three groups (GIII-V) with retaining intravesically instillated ameliorating agents for 90 min by urethral ligation until sacrifice, and one group (GVI) with freely voiding after intravesical EPI instillation. The retention groups were further classified into null-treated- (GIII), EPI- (GIV), and vehicle group (GV). All rats were euthanized 24 h after CYP injection. The UPII and α1-adrenergic receptors (AR) levels were measured with real-time polymerase chain reaction (RT-PCR) method and the morphological changes were also evaluated. CYP induced severe cystitis and decreased vesical UPII mRNA level. The EPI-treated groups had showed attenuation effects against submucosal edema and hemorrhage, and preserved UPII expression. Concurrently, intravesical EPI resulted in a significant preservation of both subtypes of α1A- and α1B AR expressions, which was well correlated with the hemostatic pattern in the samples. The obstructed and null-treated group (GIII) revealed severe cystitis and maximally decreased UPII levels, and the diluting effect of vehicle (GV) on CYP toxicity was insignificant on UPII preservation. The UPII level of RT-PCR was well correlated with the UPII immunohistological expression and their morphological changes. Intravesical instillation of EPI preserves UPII expression and attenuates the toxic responses in the bladder in CYP-induced rat cystitis.
Department of Urology, Dankook University College of Medicine, 359 Manghyang-ro, Dongnam-gu, Cheonan 330-715, South Korea.
Yoon Soo
YS
Kyung
Heeyoon
H
Park
Gilho
G
Lee
D000283:Administration, Intravesical; D000322:Adrenergic Agonists / Q000494:pharmacology*; D058646:Adrenergic alpha-1 Receptor Agonists / Q000494:pharmacology; D000477:Alkylating Agents; D000818:Animals; D003520:Cyclophosphamide; D003556:Cystitis / Q000139:chemically induced / Q000378:metabolism*; D004837:Epinephrine / Q000494:pharmacology*; D005260:Female; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases / Q000378:metabolism; D007150:Immunohistochemistry; D008855:Microscopy, Electron, Scanning; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D060888:Real-Time Polymerase Chain Reaction; D018340:Receptors, Adrenergic, alpha-1 / Q000096:biosynthesis; D001743:Urinary Bladder / Q000187:drug effects / Q000378:metabolism*; D014546:Urinary Catheterization; D060170:Uroplakin II / Q000037:antagonists & inhibitors / Q000096:biosynthesis*
D000322:Adrenergic Agonists; D058646:Adrenergic alpha-1 Receptor Agonists; D000477:Alkylating Agents; D012333:RNA, Messenger; D018340:Receptors, Adrenergic, alpha-1; D060170:Uroplakin II; D003520:Cyclophosphamide; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases; D004837:Epinephrine